Pfizer Corporation

Other

Warner-lambert Company

Ernest S Hamanaka

John G Stam

George Chang

Peter Bertinato

Ralph P Robinson

Derek Lawrence Tickner

Cheryl M Hayward

Marcus D Ewing

Michel A Couturier

Yuhpyng Liang Chen

Roger B Ruggeri

Angel Guzman-Perez

Peter A McCarthy

Frederick J Walker

Christian J Mularski

Ronald Thure Wester

Andrew Simon Bell

Joel Michael Hawkins

John L LaMattina

Michael S Kellogg

Douglas Alan Scully

Blanda Luzia Stammen

Marcus E Kehrli, Jr

Thien Truong

Thien V Truong

Ronald T Webster

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R&#x2014;R, X, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Substituted quinoline compounds

This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R-R, X, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.

Triamide-substituted heterobicyclic compounds

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

Substituted heteroaryl- and phenylsulfamoyl compounds

NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia

The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.

Use of corticotropin releasing factor antagonists and related compositions

This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents or anti-acne agents.

4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors

N-&lsqb;(substituted five-membered di- or triaza diunsaturated ring)carbonyl&rsqb; guanidine derivatives for the treatment of ischemia

This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.

Mutual prodrugs of amlodipine and atorvastatin

This invention relates to a mutual salt of amlodipine and atorvastatin, pharmaceutical compositions thereof and methods of treating angina pectoris, atherosclerosis and combined hypertension and hyperlipidemia in mammals with such a mutual salt and compositions. This invention also relates to methods of managing cardiac risk in a mammal presenting with symptoms of cardiac risk, including humans by administering such a mutual salt and compositions.

Mutual salt of amlodipine and atorvastatin

N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme

This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents.

Squalene synthetase inhibitors

Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase

Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl

Growing community of inventors

Gales Ferry, CT, United States of America

Ernest S Hamanaka